Current trends in treatment of vulvovaginitis
Efficacy of antiseptic Miramistin for treatment of polymicrobial vulvovaginitis was studied in women before initiation of assisted reproductive technologies programs. Miramistin administration was associated with improved symptoms and decreased edema and hyperemia of vaginal mucosa. In the majority of patients, normal vaginal smears were demonstrated after the therapy. Treatment efficacy was shown in 95,6% of cases. No adverse events were observed.